Evidence map›Paper›PMID 42905998›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2026

Application of Optic Neuritis Diagnostic Criteria in Autoimmune Paraneoplastic CRMP5 Optic Neuropathy and Development of the "CRMP" Score.

Alessandro Dinoto, Devon A Cohen, Laura Cacciaguerra, Nanthaya Tisavipat, Stephanie B Syc-Mazurek, Vanda A Lennon, M Tariq Bhatti, Deena A Tajfirouz, Kevin D Chodnicki, Sean J Pittock and 2 more

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessandro DinotoDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-3249-4792
Devon A CohenDepartment of Ophthalmology, Cleveland Clinic Foundation, OH.ORCID 0000-0002-0160-8435
Laura CacciaguerraDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-9342-2410
Nanthaya TisavipatDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4021-6450
Stephanie B Syc-MazurekDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-9549-6648
Vanda A LennonDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-1910-1576
M Tariq BhattiDepartment of Ophthalmology, The Permanente Medical Group, Kaiser Permanente-Northern California, Roseville, CA.ORCID 0000-0001-7190-5630
Deena A TajfirouzDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8419-8728
Kevin D ChodnickiDepartment of Ophthalmology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6815-8272
Sean J PittockDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6140-5584
Eoin P FlanaganDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6661-2910
John J ChenDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-3644-7528

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCollapsin response-mediator protein 5 (CRMP5)-IgG is an acknowledged biomarker in the International Consortium on Optic Neuritis (ICON) diagnostic criteria for optic neuritis (ON), but these criteria have not been validated in CRMP5-IgG+ON.

methodsWe evaluated the ICON and Acute Optic Neuritis Network (ACON) criteria for CRMP5-IgG+ON, using patients with late-onset (age ≥50 years) aquaporin-4-IgG-positive (AQP4-IgG+)-ON or myelin-oligodendrocyte glycoprotein antibody (MOG-IgG+)-ON for comparison. We developed the "CRMP score," based on typical CRMP5-IgG+ON clinical features, to guide CRMP5 antibody testing in ON.

resultsThe study included 17 patients with CRMP5-IgG+, 11 with AQP4-IgG+ON, and 13 with MOG-IgG+ON. Application of ICON criteria yielded no "definite ON" and 1 "probable ON" diagnosis among the 17 CRMP5-IgG+ cases, but definite ON diagnoses for 6 of 11 AQP4-IgG+ (55%, DISCUSSION: ICON and ACON criteria for ON diagnosis identified only a minority of CRMP5-IgG+ON cases; thus, we developed the "CRMP" score to aid their identification in clinical practice.

Indexed as

HydrolasesNerve Tissue ProteinsOptic NeuritisAgedAquaporin 4AutoantibodiesBiomarkersFemaleHumansImmunoglobulin GMaleMicrotubule-Associated ProteinsMiddle AgedAquaporin 4AutoantibodiesBiomarkersDPYSL5 protein, humanHydrolasesImmunoglobulin GMicrotubule-Associated ProteinsNerve Tissue Proteins

Identifiers

PMID42905998
PMCPMC13690358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.